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Pancreatic cancer: are more chemotherapy and surgery needed?
Most patients diagnosed with pancreatic cancer die from 
the disease. Although mortality from the most common 
cancers has declined in the past few decades, the mortality 
for patients with pancreatic cancer has remained high. 
On the basis of rising incidence, demographic data, and 
survival projections, pancreatic cancer is predicted to 
become the second most deadly cancer in the near future.1
Pancreatic cancer is curable only in a small minority of 
patients with localised and resectable tumours, which 
accounts for only 5–10% of the cases, and only 10–20% 
of patients survive more than 5 years after surgery. With 
such bleak figures, every attempt made to improve 
the survival rates of patients with pancreatic cancer 
should be welcomed. This is the aim of the ESPAC-4 trial 
published in The Lancet.2
John Neoptolemos and colleagues report the first 
results of the ESPAC-4 trial for the pancreatic cancer 
cohort.2 This was a multicentre, open-label, randomised 
trial of gemcitabine alone or in combination with 
capecitabine in the adjuvant setting for completely 
resected (R0 or R1) ductal pancreatic adenocarcinoma. 
The data show a significant improvement of median 
overall survival with an absolute increase of 2·5 months 
for the experimental chemotherapy combination 
group (28·0 months compared with 25·5 months in 
the standard gemcitabine group; hazard ratio [HR] for 
overall survival 0·82 [95% CI 0·68–0·98], p=0·032). The 
5-year survival rates show an absolute improvement of 
12·5%, with 28·8% of patients alive in the combination 
group versus 16·3% in the gemcitabine group. The 
toxicities of the combination group were as expected 
and more pronounced but easily manageable with 
no detrimental effect on quality of life. The authors 
conclude that the combination of gemcitabine and 
capecitabine is now the treatment of choice in the 
adjuvant setting following resection for pancreatic 
ductal adenocarcinoma.
These results open the field to several questions. 
Can an increase in chemotherapy cure more patients 
in a cancer considered for more than 60 years to be 
chemoresistant? Do the figures from the ESPAC-4 trial 
at 5 years really represent patients cured of pancreatic 
cancer? How can we now improve the survival of 
patients with pancreatic cancer further? Do we need to 
give patients more surgery or more chemotherapy?
First, the paradigm of pancreatic cancer as a 
chemoresistant tumour has been largely undermined 
in the past 5 years.3 In the metastatic setting, 
oncologists can now choose between diverse 
monotherapy or a combination of gemcitabine, 
fluorouracil, nab-paclitaxel, oxaliplatin, irinotecan, 
and liposomal irinotecan. This means there are more 
chemotherapy drugs available for pancreatic cancer 
than for colon cancer.
A meta-analysis of adjuvant trials in pancreatic 
cancer published 10 years ago showed that adjuvant 
chemotherapy gave patients only an extra 3 months 
of median survival time, without offering a cure.4 So 
does the addition of capecitabine to gemcitabine in the 
adjuvant setting of pancreatic cancer really translate 
into more patients being cured? In the ESPAC-4 trial, 
the 5-year relapse-free survival figures were 11·9% 
(95% CI 7·8–16·9) in the gemcitabine group and 
18·6% (13·8–24·0) in the combination group, giving 
an absolute difference of 6·9%, but these were only 
estimates. The authors also state from the raw data 
that at the time of analysis, tumour recurrence was 
observed in 243 (66·4%) patients in the gemcitabine 
group and 236 (64·8%) in the combination group. 
Additionally, 43 (11·7%) patients in the gemcitabine 
group and 35 (9·6%) patients in the combination group 
died without recurrence. Therefore, the number of 
patients alive without disease at the end of the analysis 
was 80 (21·8%) patients in the gemcitabine group 
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and 93 (25·5%) patients in the combination group; an 
absolute improvement and likely cure rate of 3·7%. This 
means that roughly we need to treat 25 patients with 
the combination of gemcitabine and capecitabine to 
save one more life. Of course, this further adds to the 
other gains achieved with the previous ESPAC trials as 
discussed by the authors. As for cure, more follow-up 
is needed to ascertain that this is the case and not only 
prolongation of survival. No patient has yet crossed 
the 5-year survival boundary, with a median follow-
up in the current analysis of 43·2 months, ranging 
from 39·7 to 45·5. A more recent Bayesian network 
meta-analysis showed that adjuvant fluorouracil 
or gemcitabine reduced mortality after surgery by 
about a third, supporting the idea of likely cure in the 
present trial.5
So, even if modest, these figures are encouraging in a 
disease with such high mortality and clearly establishes 
the combination of gemcitabine and capecitabine 
as a new standard of care in the adjuvant setting of 
pancreatic ductal adenocarcinoma.
How can we further improve these results in the 
future? There is clearly a need for some kind of 
biomarker that could guide the choice of treatment or 
even surgery. The results of several other large adjuvant 
trials with new drugs or a combination of drugs are also 
eagerly awaited and it is likely that more chemotherapy 
will translate into more patients being cured. But again, 
this will be only for a small subset of patients with 
pancreatic cancer who received surgery.
More surgery is therefore clearly needed if we want 
to cure more patients, but more surgery means 
the possibility to offer surgery earlier in the disease 
evolution, and as a consequence more often. An earlier 
diagnosis would allow surgery to be offered earlier, for 
example, by the appropriate screening of individuals 
with higher risk for pancreatic cancer,6 or for borderline 
resectable or unresectable patients, by the use of 
new neoadjuvant therapeutic approaches.7 Surgical 
technique itself is well defined, with clear anatomic 
landmarks, and standardised techniques, including 
portal vein resection when necessary. Another positive 
aspect is the enhanced recovery pathway such as ERAS 
(Enhanced Recovery After Surgery) that significantly 
decreases postoperative complications.8 This is of 
importance as fit patients after surgery are more 
likely to tolerate 6 months of adjuvant chemotherapy 
without interruption.
We clearly need to provide more surgery for patients 
especially those with R0 resections since this is the 
population benefiting most from postoperative 
chemotherapy in ESPAC-4 with a median survival of 
27·9 months (95% CI 23·8–34·6) in the gemcitabine 
group, reaching 39·5 months (32·0–58·0) in the 
combination group versus 23·0 months (21·6–26·2) in 
the gemcitabine group and 23·7 months (20·7–27·1) in 
the combination group in R1 patients.
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